FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039404976> ?p ?o ?g. }

• W3039404976 endingPage "2884" @default.
• W3039404976 startingPage "2876" @default.
• W3039404976 abstract "Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC), is poorly differentiated and highly aggressive. Treatment is limited, and the prognosis is poor. Pembrolizumab is an anti-programmed death (PD)-1 antibody with good efficacy in NSCLC. Recent studies have demonstrated that PD-ligand 1 (PD-L1) overexpression is common in PSCs, which suggests that anti-PD-L1 treatment is an ideal option. However, the response to pembrolizumab in PSC has not been studied.We present a PSC case with PD-L1 overexpression that significantly benefited from pembrolizumab. A 73-year-old Chinese male was detected with a right lung lesion. Pathological analysis of the right upper lobectomy confirmed PSC. The PD-L1 test revealed overexpression (TPS: 90%). Multiple metastases occurred 1 mo after surgery, representing stage IV PSC. Neither first-line chemotherapy nor second-line antiangiogenic agents showed any benefit. Radiotherapy (1200 cGy) was administered to relieve chest wall pain. The patient received the PD-1 inhibitor pembrolizumab (100 mg) as third-line therapy; however, because of fever and severe infection, he refused to receive immunotherapy any longer. Thus, only one dose of pembrolizumab was administered. Deep sustained remission of most of the metastases was achieved except for lesions in the right adrenal gland, which first shrank and then progressed. The patient died because of disease progression in the right adrenal gland. He achieved a progression-free survival time of 8 mo and an overall survival time of 9 mo with third-line pembrolizumab.Our findings highlight and offer direct evidence of the efficacy of pembrolizumab in PD-L1-overexpressing PSCs. Combined radiotherapy and immunotherapy may enhance treatment efficacy." @default.
• W3039404976 created "2020-07-10" @default.
• W3039404976 creator A5002744113 @default.
• W3039404976 creator A5003039278 @default.
• W3039404976 creator A5007778550 @default.
• W3039404976 creator A5039805249 @default.
• W3039404976 creator A5043826632 @default.
• W3039404976 creator A5047904768 @default.
• W3039404976 creator A5051480539 @default.
• W3039404976 creator A5059912107 @default.
• W3039404976 date "2020-07-06" @default.
• W3039404976 modified "2023-09-27" @default.
• W3039404976 title "Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report" @default.
• W3039404976 cites W1205148714 @default.
• W3039404976 cites W1970512876 @default.
• W3039404976 cites W2018302773 @default.
• W3039404976 cites W2030511761 @default.
• W3039404976 cites W2052727153 @default.
• W3039404976 cites W2087459740 @default.
• W3039404976 cites W2093895424 @default.
• W3039404976 cites W2121386312 @default.
• W3039404976 cites W2198093519 @default.
• W3039404976 cites W2299408353 @default.
• W3039404976 cites W2397647271 @default.
• W3039404976 cites W2467224355 @default.
• W3039404976 cites W2527905628 @default.
• W3039404976 cites W2560367415 @default.
• W3039404976 cites W2566627613 @default.
• W3039404976 cites W2572174216 @default.
• W3039404976 cites W2595413783 @default.
• W3039404976 cites W2773934589 @default.
• W3039404976 cites W2779162158 @default.
• W3039404976 cites W2789227594 @default.
• W3039404976 cites W2793368960 @default.
• W3039404976 cites W2796582438 @default.
• W3039404976 cites W2890566493 @default.
• W3039404976 cites W2906211910 @default.
• W3039404976 cites W2911314865 @default.
• W3039404976 cites W2919324052 @default.
• W3039404976 cites W2922707684 @default.
• W3039404976 doi "https://doi.org/10.12998/wjcc.v8.i13.2876" @default.
• W3039404976 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7360715" @default.
• W3039404976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32742998" @default.
• W3039404976 hasPublicationYear "2020" @default.
• W3039404976 type Work @default.
• W3039404976 sameAs 3039404976 @default.
• W3039404976 citedByCount "6" @default.
• W3039404976 countsByYear W30394049762020 @default.
• W3039404976 countsByYear W30394049762021 @default.
• W3039404976 countsByYear W30394049762022 @default.
• W3039404976 countsByYear W30394049762023 @default.
• W3039404976 crossrefType "journal-article" @default.
• W3039404976 hasAuthorship W3039404976A5002744113 @default.
• W3039404976 hasAuthorship W3039404976A5003039278 @default.
• W3039404976 hasAuthorship W3039404976A5007778550 @default.
• W3039404976 hasAuthorship W3039404976A5039805249 @default.
• W3039404976 hasAuthorship W3039404976A5043826632 @default.
• W3039404976 hasAuthorship W3039404976A5047904768 @default.
• W3039404976 hasAuthorship W3039404976A5051480539 @default.
• W3039404976 hasAuthorship W3039404976A5059912107 @default.
• W3039404976 hasBestOaLocation W30394049761 @default.
• W3039404976 hasConcept C121332964 @default.
• W3039404976 hasConcept C121608353 @default.
• W3039404976 hasConcept C126322002 @default.
• W3039404976 hasConcept C141071460 @default.
• W3039404976 hasConcept C142424586 @default.
• W3039404976 hasConcept C143998085 @default.
• W3039404976 hasConcept C2776256026 @default.
• W3039404976 hasConcept C2776694085 @default.
• W3039404976 hasConcept C2777546739 @default.
• W3039404976 hasConcept C2777701055 @default.
• W3039404976 hasConcept C2777714996 @default.
• W3039404976 hasConcept C2780057760 @default.
• W3039404976 hasConcept C2780808757 @default.
• W3039404976 hasConcept C71924100 @default.
• W3039404976 hasConcept C87355193 @default.
• W3039404976 hasConcept C90924648 @default.
• W3039404976 hasConceptScore W3039404976C121332964 @default.
• W3039404976 hasConceptScore W3039404976C121608353 @default.
• W3039404976 hasConceptScore W3039404976C126322002 @default.
• W3039404976 hasConceptScore W3039404976C141071460 @default.
• W3039404976 hasConceptScore W3039404976C142424586 @default.
• W3039404976 hasConceptScore W3039404976C143998085 @default.
• W3039404976 hasConceptScore W3039404976C2776256026 @default.
• W3039404976 hasConceptScore W3039404976C2776694085 @default.
• W3039404976 hasConceptScore W3039404976C2777546739 @default.
• W3039404976 hasConceptScore W3039404976C2777701055 @default.
• W3039404976 hasConceptScore W3039404976C2777714996 @default.
• W3039404976 hasConceptScore W3039404976C2780057760 @default.
• W3039404976 hasConceptScore W3039404976C2780808757 @default.
• W3039404976 hasConceptScore W3039404976C71924100 @default.
• W3039404976 hasConceptScore W3039404976C87355193 @default.
• W3039404976 hasConceptScore W3039404976C90924648 @default.
• W3039404976 hasIssue "13" @default.
• W3039404976 hasLocation W30394049761 @default.
• W3039404976 hasLocation W30394049762 @default.
• W3039404976 hasLocation W30394049763 @default.
• W3039404976 hasOpenAccess W3039404976 @default.

• next